DNA Damage Detection and Checkpoint Responses

Core Idea

DNA damage (double-strand breaks, single-strand breaks, base modifications) is detected by sensor kinases ATM (responding to DSBs) and ATR (responding to single-strand breaks and replication fork stalling). These kinases phosphorylate p53, stabilizing it and enabling its function as a transcription factor that activates DNA repair genes, cell cycle inhibitors (p21), and pro-apoptotic genes (Bax). This allows time for repair; if damage is irreparable, p53 triggers apoptosis or senescence, preventing transmission of mutations.

Explainer

From your study of DNA repair mechanisms, you know that cells have enzymatic systems for fixing damaged DNA — base excision repair, nucleotide excision repair, homologous recombination, and others. But repair takes time, and if a cell continues dividing while its DNA is broken, it risks passing mutations to daughter cells or suffering catastrophic chromosome rearrangements. DNA damage checkpoints solve this timing problem: they are signaling pathways that detect damage, halt the cell cycle to allow repair, and — if repair fails — permanently eliminate the damaged cell through apoptosis or senescence.

The checkpoint response begins with sensor kinases that recognize specific types of DNA lesions. ATM (ataxia-telangiectasia mutated) is activated by double-strand breaks (DSBs) — the most dangerous form of DNA damage, since a broken chromosome can be lost or rearranged during division. When a DSB occurs, the MRN complex (Mre11-Rad50-Nbs1) binds the broken ends and recruits ATM, which undergoes autophosphorylation and becomes active. ATR (ATM and Rad3-related) responds to a different signal: stretches of single-stranded DNA (ssDNA) coated with the replication protein RPA, which arise at stalled replication forks or as intermediates during repair of various lesion types. ATR is recruited to RPA-coated ssDNA via its partner protein ATRIP. Think of ATM as the alarm for broken chromosomes and ATR as the alarm for stalled replication — together, they cover the major categories of genomic threat.

Once activated, ATM and ATR phosphorylate a cascade of downstream targets that implement the checkpoint. The most important effector is p53, often called the "guardian of the genome." In undamaged cells, p53 is kept at low levels by the ubiquitin ligase MDM2, which continuously tags p53 for proteasomal degradation. When ATM or ATR phosphorylate p53, this disrupts the MDM2-p53 interaction, allowing p53 to accumulate and function as a transcription factor. Stabilized p53 activates three categories of target genes depending on the severity of damage. For repairable damage, p53 induces p21, a cyclin-dependent kinase inhibitor that blocks cell cycle progression at the G1/S checkpoint, buying time for DNA repair enzymes to work. P53 also upregulates DNA repair genes themselves. If the damage proves irreparable — assessed by the persistence of checkpoint signaling — p53 shifts to activating pro-apoptotic genes like Bax, PUMA, and Noxa, which trigger the intrinsic apoptosis pathway via mitochondrial outer membrane permeabilization. Alternatively, the cell may enter senescence, a permanent cell cycle arrest that prevents proliferation without killing the cell.

The checkpoint operates at multiple cell cycle stages, not just G1. ATM/ATR also activate the checkpoint kinases Chk1 and Chk2, which phosphorylate and inactivate the Cdc25 phosphatases required for CDK activation. This blocks entry into S phase (G1/S checkpoint), slows replication (intra-S checkpoint), and prevents entry into mitosis (G2/M checkpoint). The result is a multi-layered surveillance system: damage detected at any point in the cell cycle triggers an appropriate pause.

The clinical importance of this pathway is enormous. p53 is the most frequently mutated gene in human cancers — mutated in roughly half of all tumors. When p53 is lost, cells with DNA damage continue dividing, accumulating mutations at an accelerated rate and fueling tumor evolution. Similarly, loss of ATM causes ataxia-telangiectasia, a syndrome characterized by neurodegeneration, immunodeficiency, and extreme cancer predisposition. Understanding these checkpoints has also opened therapeutic strategies: some cancers that lack p53 become dependent on ATR for survival during replication stress, making ATR inhibitors a promising class of targeted cancer therapeutics that exploit the tumor's own checkpoint deficiency.